Literature DB >> 11160680

Temperature-sensitive transformation by an Abelson virus mutant encoding an altered SH2 domain.

C A Mainville1, K Parmar, I Unnikrishnan, L Gong, G D Raffel, N Rosenberg.   

Abstract

Abelson murine leukemia virus (Ab-MLV) encodes the v-Abl protein tyrosine kinase and induces transformation of immortalized fibroblast lines and pre-B cells. Temperature-sensitive mutations affecting the kinase domain of the protein have demonstrated that the kinase activity is absolutely required for transformation. Despite this requirement, mutations affecting other regions of v-Abl modulate transformation activity. The SH2 domain and the highly conserved FLVRES motif within it form a phosphotyrosine-binding pocket that is required for interactions between the kinase and cellular substrates. To understand the impact of SH2 alterations on Ab-MLV-mediated transformation, we studied the Ab-MLV mutant P120/R273K. This mutant encodes a v-Abl protein in which the beta B5 arginine at the base of the phosphotyrosine-binding pocket has been replaced by a lysine. Unexpectedly, infection of NIH 3T3 or pre-B cells with P120/R273K revealed a temperature-dependent transformation phenotype. At 34 degrees C, P120/R273K transformed about 10-fold fewer cells than wild-type virus of equivalent titer; at 39.5 degrees C, 300-fold fewer NIH 3T3 cells were transformed and pre-B cells were refractory to transformation. Temperature-dependent transformation was accompanied by decreased phosphorylation of Shc, a protein that interacts with the v-Abl SH2 and links the protein to Ras, and decreased induction of c-Myc expression. These data suggest that alteration of the FLVRES pocket affects the ability of v-Abl to interact with at least some of its substrates in a temperature-dependent fashion and identify a novel type of temperature-sensitive Abelson virus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160680      PMCID: PMC114091          DOI: 10.1128/JVI.75.4.1816-1823.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Versatile retroviral vectors for potential use in gene therapy.

Authors:  R G Hawley; F H Lieu; A Z Fong; T S Hawley
Journal:  Gene Ther       Date:  1994-03       Impact factor: 5.250

2.  Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.

Authors:  D Cortez; L Kadlec; A M Pendergast
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

3.  The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells.

Authors:  R L Ilaria; R A Van Etten
Journal:  Blood       Date:  1995-11-15       Impact factor: 22.113

4.  An active v-abl protein tyrosine kinase blocks immunoglobulin light-chain gene rearrangement.

Authors:  Y Y Chen; L C Wang; M S Huang; N Rosenberg
Journal:  Genes Dev       Date:  1994-03-15       Impact factor: 11.361

5.  Ras complements the carboxyl terminus of v-Abl protein in lymphoid transformation.

Authors:  K Parmar; N Rosenberg
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

6.  v-Abl-mediated apoptotic suppression is associated with SHC phosphorylation without concomitant mitogen-activated protein kinase activation.

Authors:  P J Owen-Lynch; A K Wong; A D Whetton
Journal:  J Biol Chem       Date:  1995-03-17       Impact factor: 5.157

7.  Reduced phosphotyrosine binding by the v-Src SH2 domain is compatible with wild-type transformation.

Authors:  M Tian; G S Martin
Journal:  Oncogene       Date:  1996-02-15       Impact factor: 9.867

8.  In vivo association of v-Abl with Shc mediated by a non-phosphotyrosine-dependent SH2 interaction.

Authors:  G D Raffel; K Parmar; N Rosenberg
Journal:  J Biol Chem       Date:  1996-03-01       Impact factor: 5.157

9.  A role for c-Abl in c-myc regulation.

Authors:  K K Wong; J D Hardin; S Boast; C L Cooper; K T Merrell; T G Doyle; S P Goff; K L Calame
Journal:  Oncogene       Date:  1995-02-16       Impact factor: 9.867

10.  Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene.

Authors:  C L Sawyers; J McLaughlin; O N Witte
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

View more
  12 in total

1.  Gag influences transformation by Abelson murine leukemia virus and suppresses nuclear localization of the v-Abl protein.

Authors:  Chae-Ryun Yi; Naomi Rosenberg
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

2.  Hypomorphic Rag mutations can cause destructive midline granulomatous disease.

Authors:  Suk See De Ravin; Edward W Cowen; Kol A Zarember; Narda L Whiting-Theobald; Douglas B Kuhns; Netanya G Sandler; Daniel C Douek; Stefania Pittaluga; Pietro L Poliani; Yu Nee Lee; Luigi D Notarangelo; Lei Wang; Frederick W Alt; Elizabeth M Kang; Joshua D Milner; Julie E Niemela; Mary Fontana-Penn; Sara H Sinal; Harry L Malech
Journal:  Blood       Date:  2010-05-20       Impact factor: 22.113

3.  Disruption of the Shc/Grb2 complex during abelson virus transformation affects proliferation, but not apoptosis.

Authors:  Linda B Baughn; Naomi Rosenberg
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  The extreme carboxyl terminus of v-Abl is required for lymphoid cell transformation by Abelson virus.

Authors:  David Warren; Deborah S Griffin; Celine Mainville; Naomi Rosenberg
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

5.  SH2-containing inositol 5'-phosphatase inhibits transformation of Abelson murine leukemia virus.

Authors:  Shawn P Fessler; Naomi Rosenberg; Linda B Baughn
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

Review 6.  Lymphocyte development: integration of DNA damage response signaling.

Authors:  Jeffrey J Bednarski; Barry P Sleckman
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

7.  Changes in p19Arf localization accompany apoptotic crisis during pre-B-cell transformation by Abelson murine leukemia virus.

Authors:  Rebekah Stackpole Zimmerman; Naomi Rosenberg
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

8.  Absence of p53 complements defects in Abelson murine leukemia virus signaling.

Authors:  Indira Unnikrishnan; Naomi Rosenberg
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  Mutations affecting the MA portion of the v-Abl protein reveal a conserved role of Gag in Abelson murine leukemia virus (MLV) and Moloney MLV.

Authors:  Chae-ryun Yi; Naomi Rosenberg
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

10.  p16(Ink4a) interferes with Abelson virus transformation by enhancing apoptosis.

Authors:  Zohar Sachs; Norman E Sharpless; Ronald A DePinho; Naomi Rosenberg
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.